Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI/Baxalta Withdraw Pacritinib NDA Following More Deaths

This article was originally published in Scrip

Executive Summary

Things have gone from bad to worse for CTI BioPharma Corp. this week. Shares lost 60% of their value to close at $0.44 on Feb. 8 following news the US FDA had placed a partial clinical hold on myelofibrosis treatment candidate pacritinib. And now, the company has received further communication from the FDA that the IND for pacritinib has been placed on full clinical hold.

Advertisement

Related Content

Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi
CTI BioPharma’s Pacritinib Meets One Co-Primary Endpoint, Just Misses Another, In PERSIST-2

Topics

Advertisement
UsernamePublicRestriction

Register

SC064453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel